Cargando…

Hyperlipidemia, statin use and dengue severity

Multiple in vitro and mice model studies suggest statins may attenuate dengue severity. However, little is known about statin use and dengue severity in adult dengue patients with hyperlipidemia. We conducted a retrospective cohort study from 2004–2008 and 2012–2013 in Tan Tock Seng Hospital, Singap...

Descripción completa

Detalles Bibliográficos
Autores principales: Chia, Po Ying, Htun, Htet Lin, Ling, Wei Ping, Leo, Yee Sin, Yeo, Tsin Wen, Lye, David Chien Boon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249290/
https://www.ncbi.nlm.nih.gov/pubmed/30464247
http://dx.doi.org/10.1038/s41598-018-35334-2
_version_ 1783372714684186624
author Chia, Po Ying
Htun, Htet Lin
Ling, Wei Ping
Leo, Yee Sin
Yeo, Tsin Wen
Lye, David Chien Boon
author_facet Chia, Po Ying
Htun, Htet Lin
Ling, Wei Ping
Leo, Yee Sin
Yeo, Tsin Wen
Lye, David Chien Boon
author_sort Chia, Po Ying
collection PubMed
description Multiple in vitro and mice model studies suggest statins may attenuate dengue severity. However, little is known about statin use and dengue severity in adult dengue patients with hyperlipidemia. We conducted a retrospective cohort study from 2004–2008 and 2012–2013 in Tan Tock Seng Hospital, Singapore on adult dengue patients with hyperlipidemia, comparing those with and without statin usage at hospitalization in terms of primary outcome of dengue hemorrhagic fever (DHF) or shock syndrome (DSS), and severe dengue (SD). Of 13,975 subjects screened, 257 dengue patients were included; 191 (74.3%) were statin users and 66 (25.7%) were non-users. Compared with non-users, statin use was not associated with decreased risk of DHF/DSS (adjusted risk ratio [aRR] = 0.66, 95%confidence interval [CI]: 0.41–1.08, P = 0.10) and SD (aRR = 1.43, 95%CI: 0.84–2.43, P = 0.19). Therefore, statin usage had minimal effect on dengue severity in our study population in Singapore.
format Online
Article
Text
id pubmed-6249290
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-62492902018-11-28 Hyperlipidemia, statin use and dengue severity Chia, Po Ying Htun, Htet Lin Ling, Wei Ping Leo, Yee Sin Yeo, Tsin Wen Lye, David Chien Boon Sci Rep Article Multiple in vitro and mice model studies suggest statins may attenuate dengue severity. However, little is known about statin use and dengue severity in adult dengue patients with hyperlipidemia. We conducted a retrospective cohort study from 2004–2008 and 2012–2013 in Tan Tock Seng Hospital, Singapore on adult dengue patients with hyperlipidemia, comparing those with and without statin usage at hospitalization in terms of primary outcome of dengue hemorrhagic fever (DHF) or shock syndrome (DSS), and severe dengue (SD). Of 13,975 subjects screened, 257 dengue patients were included; 191 (74.3%) were statin users and 66 (25.7%) were non-users. Compared with non-users, statin use was not associated with decreased risk of DHF/DSS (adjusted risk ratio [aRR] = 0.66, 95%confidence interval [CI]: 0.41–1.08, P = 0.10) and SD (aRR = 1.43, 95%CI: 0.84–2.43, P = 0.19). Therefore, statin usage had minimal effect on dengue severity in our study population in Singapore. Nature Publishing Group UK 2018-11-21 /pmc/articles/PMC6249290/ /pubmed/30464247 http://dx.doi.org/10.1038/s41598-018-35334-2 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Chia, Po Ying
Htun, Htet Lin
Ling, Wei Ping
Leo, Yee Sin
Yeo, Tsin Wen
Lye, David Chien Boon
Hyperlipidemia, statin use and dengue severity
title Hyperlipidemia, statin use and dengue severity
title_full Hyperlipidemia, statin use and dengue severity
title_fullStr Hyperlipidemia, statin use and dengue severity
title_full_unstemmed Hyperlipidemia, statin use and dengue severity
title_short Hyperlipidemia, statin use and dengue severity
title_sort hyperlipidemia, statin use and dengue severity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249290/
https://www.ncbi.nlm.nih.gov/pubmed/30464247
http://dx.doi.org/10.1038/s41598-018-35334-2
work_keys_str_mv AT chiapoying hyperlipidemiastatinuseanddengueseverity
AT htunhtetlin hyperlipidemiastatinuseanddengueseverity
AT lingweiping hyperlipidemiastatinuseanddengueseverity
AT leoyeesin hyperlipidemiastatinuseanddengueseverity
AT yeotsinwen hyperlipidemiastatinuseanddengueseverity
AT lyedavidchienboon hyperlipidemiastatinuseanddengueseverity